9-Months and 12-Months Safety and Exploratory Efficacy Data of ANAVEX 2-73 in a Phase 2a Study in Mild-to-Moderate Alzheimer’s Disease Patients.

9th Clinical Trials on Alzheimer’s Disease (CTAD)  2016, San Diego, CA

Associate Professor Stephen Macfarlane,  FRANZCP

View Presentation

Share this: